Fc-Receptor Interactions Regulate Both Cytotoxic and Immunomodulatory Therapeutic Antibody Effector Functions
暂无分享,去创建一个
[1] R. Kimberly,et al. FcγRs Modulate Cytotoxicity of Anti-Fas Antibodies: Implications for Agonistic Antibody-Based Therapeutics1 , 2003, The Journal of Immunology.
[2] H. Eisen. Affinity Enhancement of Antibodies: How Low-Affinity Antibodies Produced Early in Immune Responses Are Followed by High-Affinity Antibodies Later and in Memory B-Cell Responses , 2014, Cancer Immunology Research.
[3] J. Ravetch,et al. Fcγ receptors as regulators of immune responses , 2008, Nature Reviews Immunology.
[4] J. Ravetch,et al. Divergent Immunoglobulin G Subclass Activity Through Selective Fc Receptor Binding , 2005, Science.
[5] R. Steinman,et al. Selective blockade of inhibitory Fcgamma receptor enables human dendritic cell maturation with IL-12p70 production and immunity to antibody-coated tumor cells. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[6] R. Levy,et al. Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors. , 1992, The New England journal of medicine.
[7] T. Tedder,et al. Antibody isotype-specific engagement of Fcγ receptors regulates B lymphocyte depletion during CD20 immunotherapy , 2006, The Journal of experimental medicine.
[8] J. Friedberg,et al. Rituximab immunotherapy results in the induction of a lymphoma idiotype-specific T-cell response in patients with follicular lymphoma: support for a "vaccinal effect" of rituximab. , 2009, Blood.
[9] J. Ravetch,et al. Differential Fc-Receptor Engagement Drives an Anti-tumor Vaccinal Effect , 2015, Cell.
[10] Holly M Horton,et al. Potent in vitro and in vivo activity of an Fc-engineered anti-CD19 monoclonal antibody against lymphoma and leukemia. , 2008, Cancer research.
[11] G. Dranoff,et al. Activating Fc γ receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies , 2013, The Journal of experimental medicine.
[12] W. Fridman,et al. Long-lasting antitumor protection by anti-CD20 antibody through cellular immune response. , 2010, Blood.
[13] M. Ychou,et al. Impact of Fc{gamma}RIIa-Fc{gamma}RIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] K. Rafiq,et al. Immune complex-mediated antigen presentation induces tumor immunity. , 2002, The Journal of clinical investigation.
[15] L. Brady. Antibody-Mediated Immunomodulation: a Strategy To Improve Host Responses against Microbial Antigens , 2005, Infection and Immunity.
[16] K. Haas,et al. The Innate Mononuclear Phagocyte Network Depletes B Lymphocytes through Fc Receptor–dependent Mechanisms during Anti-CD20 Antibody Immunotherapy , 2004, The Journal of experimental medicine.
[17] G. Dranoff,et al. OX40 engagement depletes intratumoral Tregs via activating FcγRs, leading to antitumor efficacy , 2014, Immunology and cell biology.
[18] Michael Hallek,et al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. , 2014, The New England journal of medicine.
[19] C. Ries,et al. GA201 (RG7160): A Novel, Humanized, Glycoengineered Anti-EGFR Antibody with Enhanced ADCC and Superior In Vivo Efficacy Compared with Cetuximab , 2012, Clinical Cancer Research.
[20] P. Palese,et al. Broadly neutralizing hemagglutinin stalk–specific antibodies require FcγR interactions for protection against influenza virus in vivo , 2014, Nature Medicine.
[21] M. Lindorfer,et al. Immunotherapeutic mechanisms of anti-CD20 monoclonal antibodies. , 2008, Current opinion in immunology.
[22] J. Ravetch,et al. Antitumor activities of agonistic anti-TNFR antibodies require differential FcγRIIB coengagement in vivo , 2013, Proceedings of the National Academy of Sciences.
[23] D. Petrylak,et al. Augmented HER-2–Specific Immunity during Treatment with Trastuzumab and Chemotherapy , 2007, Clinical Cancer Research.
[24] H. Koeppen,et al. Isotype-Dependent Inhibition of Tumor Growth In Vivo by Monoclonal Antibodies to Death Receptor 4 , 2001, The Journal of Immunology.
[25] W. Weng,et al. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] A. Yang,et al. An Fcγ receptor-dependent mechanism drives antibody-mediated target-receptor signaling in cancer cells. , 2011, Cancer cell.
[27] J. Ravetch,et al. Fcgamma receptors as regulators of immune responses. , 2008, Nature reviews. Immunology.
[28] P. Ricciardi-Castagnoli,et al. Fcγ Receptor–mediated Induction of Dendritic Cell Maturation and Major Histocompatibility Complex Class I–restricted Antigen Presentation after Immune Complex Internalization , 1999, The Journal of experimental medicine.
[29] J. Wolchok,et al. Targeting immune checkpoints: releasing the restraints on anti-tumor immunity for patients with melanoma. , 2012, Cancer journal.
[30] G. Rabinovich,et al. Immunosuppressive strategies that are mediated by tumor cells. , 2007, Annual review of immunology.
[31] L. Presta,et al. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets , 2000, Nature Medicine.
[32] M. Sliwkowski,et al. Afucosylated Antibodies Increase Activation of FcγRIIIa-Dependent Signaling Components to Intensify Processes Promoting ADCC , 2014, Cancer Immunology Research.
[33] J. Wolchok,et al. Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti–CTLA-4 therapy against melanoma , 2013, The Journal of experimental medicine.
[34] J. Ravetch,et al. Mouse model recapitulating human Fcγ receptor structural and functional diversity , 2012, Proceedings of the National Academy of Sciences.
[35] G. Salles,et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. , 2002, Blood.
[36] Carlo M. Croce,et al. Causes and Consequences of MicroRNA Dysregulation , 2012, Cancer journal.
[37] D. Mann,et al. Generation of CD4(+) and CD8(+) T lymphocyte responses by dendritic cells armed with PSA/anti-PSA (antigen/antibody) complexes. , 2001, Clinical immunology.
[38] J. Ravetch,et al. Inducing Tumor Immunity through the Selective Engagement of Activating Fcγ Receptors on Dendritic Cells , 2002, The Journal of experimental medicine.
[39] M. Cragg,et al. Interaction with FcγRIIB Is Critical for the Agonistic Activity of Anti-CD40 Monoclonal Antibody , 2011, The Journal of Immunology.
[40] C. Horak,et al. Nivolumab plus ipilimumab in advanced melanoma. , 2013, The New England journal of medicine.
[41] J. Ravetch,et al. Antibodies, Fc receptors and cancer. , 2007, Current opinion in immunology.
[42] H. Scher,et al. Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.
[43] T. Lynch,et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.
[44] Lai-Xi Wang,et al. Structural characterization of anti-inflammatory immunoglobulin G Fc proteins. , 2014, Journal of molecular biology.
[45] J. Ravetch,et al. A Novel Role for the IgG Fc Glycan: The Anti-inflammatory Activity of Sialylated IgG Fcs , 2010, Journal of Clinical Immunology.
[46] K. Shitara,et al. The Absence of Fucose but Not the Presence of Galactose or Bisecting N-Acetylglucosamine of Human IgG1 Complex-type Oligosaccharides Shows the Critical Role of Enhancing Antibody-dependent Cellular Cytotoxicity* , 2003, The Journal of Biological Chemistry.
[47] U. Jäger,et al. Cross-Priming of Cytotoxic T Cells Promoted by Apoptosis-Inducing Tumor Cell Reactive Antibodies? , 2002, Journal of Clinical Immunology.
[48] M. Cragg,et al. Conformation of the Human Immunoglobulin G2 Hinge Imparts Superagonistic Properties to Immunostimulatory Anticancer Antibodies , 2015, Cancer cell.
[49] J. Ravetch,et al. A general requirement for FcγRIIB co-engagement of agonistic anti-TNFR antibodies , 2012, Cell cycle.
[50] J. Ravetch,et al. Inhibitory Fcγ Receptor Engagement Drives Adjuvant and Anti-Tumor Activities of Agonistic CD40 Antibodies , 2011, Science.
[51] A. Korman,et al. Anti-CTLA-4 Antibodies of IgG2a Isotype Enhance Antitumor Activity through Reduction of Intratumoral Regulatory T Cells , 2013, Cancer Immunology Research.
[52] S. Iida,et al. Non-fucosylated therapeutic antibodies as next-generation therapeutic antibodies , 2006, Expert opinion on biological therapy.
[53] J. Ravetch,et al. FcγRs in health and disease. , 2011, Current topics in microbiology and immunology.
[54] Hervé Watier,et al. From the bench to the bedside: ways to improve rituximab efficacy. , 2004, Blood.
[55] R. Noelle,et al. Molecular mechanism and function of CD40/CD40L engagement in the immune system , 2009, Immunological reviews.
[56] J. Ravetch,et al. Novel roles for the IgG Fc glycan , 2012, Annals of the New York Academy of Sciences.
[57] Eyal Bar-Or,et al. Synergistic Effect of Dendritic Cell Vaccination and Anti-CD20 Antibody Treatment in the Therapy of Murine Lymphoma , 2009, Journal of immunotherapy.
[58] J. Ravetch,et al. Type I and type II Fc receptors regulate innate and adaptive immunity , 2014, Nature Immunology.
[59] A. Tolcher,et al. Phase I trial of a murine antibody to MUC1 in patients with metastatic cancer: evidence for the activation of humoral and cellular antitumor immunity. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.
[60] A. Musolino,et al. Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[61] J. Ravetch,et al. Protection in antibody- and T cell-mediated autoimmune diseases by antiinflammatory IgG Fcs requires type II FcRs , 2015, Proceedings of the National Academy of Sciences.
[62] J. Ravetch,et al. General mechanism for modulating immunoglobulin effector function , 2013, Proceedings of the National Academy of Sciences.
[63] C. Kallenberg,et al. Inflammation in autoimmunity: receptors for IgG revisited. , 2001, Trends in immunology.
[64] M. Nussenzweig,et al. Broadly Neutralizing Anti-HIV-1 Antibodies Require Fc Effector Functions for In Vivo Activity , 2014, Cell.